Members of the FDA's arthritis drugs advisory committee on Friday voted 10-4 in favor of recommending that the agency approve a new drug application (NDA) for lesinurad, a gout drug developed by Astrazeneca plc subsidiary Ardea Biosciences Inc. to improve upon standard-of-care treatment for the condition.